1.The Non-Squamous Cell Cancers of the Larynx.
Joon Bum JOO ; Seung Joo YOO ; Soon Yuhl NAM ; Sang Yoon KIM
Korean Journal of Otolaryngology - Head and Neck Surgery 2001;44(11):1199-1205
BACKGROUND AND OBJECTIVES: The majority of laryngeal tumors are known to be SCC (squamous cell carcinoma). Non-SCC (non-squamous cell cancers) of the larynx represent a diverse spectrum of diseases with different prognosis and ratio-nales of management from SCC. Therapeutic options to these tumors depend on their histopathological characteristics and clinical behaviors. The purpose of this study was to assess the unique aspects of the non-SCC and to draw diagnosis and provide management options and prognostic variables. MATERIALS AND METHOD: Eleven non-SCC of the larynx from the 212 patients who were diagnosed with larynx cancer during their 3-year visits from 1997 to 2000 were reviewed retrospectively. RESULTS: The incidence of non-SCC was 5.2%. Pathology of non-SCC revealed 3 cases of malignant lymphoma, 2 cases of verrucous cell carcinoma and neuroendocrine carcinoma one case each of basaloid squamous cell carninoma, salivary duct carcinoma, adenocarcinoma, and spindle cell carcinoma. The most common site of origin was supraglottis (6 case, 56.5%), followed by glottis (4 cases, 36.4%) and subglottis (2 cases, 17.2%). Non-Hodgkin's lymphomas and basaloid squamous cell carninoma were treated by chemotherapy. The remaining cases were treated with surgery followed by postoperative radio-therapy or postoperative chemotherapy. The mean follow-up period was 26.8 months (12-43 months). CONCLUSION: Non-SCC accounts for approximately 5.2% of all malignancies of the larynx. Tissue biopsy is the most important diagnostic tool for the non-SCC of the larynx and the tissue sample must be obtained from the deep portion of the submucosal layer. Except for malignant lymphomas, the combined therapy that includes surgery would be the best method of treatment for non-SCC.
Adenocarcinoma
;
Biopsy
;
Carcinoma, Neuroendocrine
;
Diagnosis
;
Drug Therapy
;
Follow-Up Studies
;
Glottis
;
Humans
;
Incidence
;
Laryngeal Neoplasms
;
Larynx*
;
Lymphoma
;
Lymphoma, Non-Hodgkin
;
Pathology
;
Prognosis
;
Retrospective Studies
;
Salivary Ducts
2.Clinical features of 50 cases of primary gastric lymphoma.
Jin HUANG ; Meizuo ZHONG ; Youhong TANG ; Jianhong LU ; Xiaoling LI ; Guiyuan LI
Journal of Central South University(Medical Sciences) 2012;37(10):997-1002
OBJECTIVE:
To analyze the clinical characteristics of primary gastric lymphoma (PGL) and to improve its diagnosis and treatment.
METHODS:
The clinical manifestations, diagnosis, treatments and history of 50 PGL patients, who were hospitalized from September 2005 to September 2009, were reviewed and analyzed.
RESULTS:
The main manifestation of PGL was epigastric pain with infrequent systemic symptoms, such as stomach ache, abdominal discomfort, vomit, black stool, loss of appetite, fever, feeble, and skinny. Pathological examination indicated that only 1 patient had T cell lymphoma while the rest 49 had B cell lymphoma. Fourteen had mucosa-associated lymphoid tissue lymphoma (MALT), 35 had diffuse large B cell lymphoma (DLBCL), and 2 had both DLBCL and MALT (DLBCML). All the 50 patients received chemotherapy, and 12 underwent surgical treatment besides chemotherapy. Fourteen out of the 49 patients with B cell lymphoma received rituximab together with chemotherapy, and 35 received chemotherapy alone. The 2-year survival rate in the patients receiving rituximab together with chemotherapy was higher than that in the patients receiving chemotherapy alone (85.7% vs 77.1%, P< 0.05). The 2-year survival rate in patients of clinical stage I-II was higher than that in patients of clinical stage III-IV (90.9% vs 71.4%, P< 0.05).
CONCLUSION
The main clinical manifestation of PGL patients is non-specific gastrointestinal symptoms, among which abdominal pain is most common. The clinical examination mainly relies on pathological examinations, and the most common pathological type of primary gastric lymphoma is DLBCL. The main treatment is chemotherapy, and the prognosis is related to the clinical stage and the use of rituximab. After the treatment, the 2-year survival rate in the 50 patients reaches 80.0%.
Antibodies, Monoclonal, Murine-Derived
;
therapeutic use
;
Humans
;
Lymphoma, B-Cell, Marginal Zone
;
Lymphoma, Large B-Cell, Diffuse
;
Lymphoma, Non-Hodgkin
;
diagnosis
;
drug therapy
;
pathology
;
Prognosis
;
Retrospective Studies
;
Rituximab
;
Stomach Neoplasms
;
diagnosis
;
drug therapy
;
pathology
;
Survival Rate
3.Non-Hodgkin's lymphoma with pulmonary infiltrates simulating tuberculoma.
Tae Young YANG ; Je Jung LEE ; Hyeong Cheon PARK ; Yeo Kyeoung KIM ; Ho In HWANG ; Sang Hee CHO ; Moo Rim PARK ; Ik Joo CHUNG ; Hyeoung Joon KIM
Korean Journal of Medicine 2002;62(1):109-113
We report a 63-years-old woman who developed a nodular lesion in right upper lobe (RUL) of lung after achieving a partial response with salvage chemotherapy for relapsed non-Hodgkin's lymphoma (NHL). Previously, she had been diagnosed as NHL and tuberculous lymphadenitis resulting a complete response with 8 cycles of CHOP regimen and anti-tuberculosis medication for 1 year. CT scan of the chest showed an irregular marginated soft tissue density in RUL with internal punctate calcifications and this lesion was difficult to discriminate between pulmonary tuberculosis and parenchymal involvement of NHL. Because the pulmonary infiltrations progressed despite empirical anti-tuberculosis medication, we performed bronchoscopic biopsy, showing diffuse large B-cell lymphoma. Thereafter, the pulmonary infiltrations were markedly improved with salvage chemotherapy. However, she died of refractory NHL despite high-dose chemotherapy with autologous peripheral blood stem cell transplantation.
Biopsy
;
Diagnosis
;
Drug Therapy
;
Female
;
Humans
;
Lung
;
Lymphoma
;
Lymphoma, B-Cell
;
Lymphoma, Non-Hodgkin*
;
Pathology
;
Peripheral Blood Stem Cell Transplantation
;
Thorax
;
Tomography, X-Ray Computed
;
Tuberculoma*
;
Tuberculosis
;
Tuberculosis, Lymph Node
;
Tuberculosis, Pulmonary
4.Diagnosis and treatment of primary colorectal non-Hodgkin's lymphoma: analysis of 52 cases.
Shuai HUANG ; Zhao-xu ZHENG ; Quan XU ; Xing-hua YUAN
Chinese Journal of Oncology 2013;35(4):305-308
OBJECTIVETo summarize and analyze the diagnosis, clinical features and therapy of primary colorectal non-Hodgkin's lymphoma (NHL).
METHODSThe clinicopathological data of 52 patients with primary colorectal NHL diagnosed and treated in our department from January 2000 to January 2010 were reviewed and analyzed retrospectively in this study.
RESULTSThis group of patients was composed of 45 cases of B cell and 7 T cell lymphomas, including 33 males and 19 females, with a male to female ratio of 1.7:1, and the age at diagnosis was 16 - 74 years old, with a median age of 50 years. The ileocecal region was most frequently involved site, acounted for 48.1%. The common symptoms encountered were abdominal pain (66.7%), diarrhea (15.6%), blood stool (24.4%), and body weight loss (8.9%). All patients were eventually diagnosed by histopathology, and the DLBCL subtype took up 64.4%. Among the 45 cases of B cell subtype, 33 cases (73.3%) were of early stage (IE and IIE confirmed), and the 5-year survival rate was 78.1%, while those of stage IIIE and IVE comprised 26.7%, with a 5-year survival rate of 45.5% (P < 0.05). The 5-year survival rate of all patients was 71.1%. Surgery was employed in 36 cases, and 9 patients received chemotherapy alone. Radical surgery could significantly increase the patients' overall survival rate, as compared with the chemotherapy alone group and palliative surgery group (P < 0.05).
CONCLUSIONSColorectal non-Hodgkin's lymphoma is a rare malignancy of the gastrointestinal tract. B cell type, male predominance and DLBCL subtype are most encountered manifestations in clinics. Multi-modality management with radical surgical resection of the primary lesion followed by standard chemotherapy, affords better local disease control, and a better survival outcome. Early detection and tailored immunotherapy can obviously prolong the long-term survival time.
Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Chemotherapy, Adjuvant ; Colorectal Neoplasms ; diagnosis ; drug therapy ; pathology ; surgery ; Cyclophosphamide ; therapeutic use ; Doxorubicin ; therapeutic use ; Female ; Follow-Up Studies ; Humans ; Lymphoma, B-Cell ; diagnosis ; drug therapy ; pathology ; surgery ; Lymphoma, Large B-Cell, Diffuse ; diagnosis ; drug therapy ; pathology ; surgery ; Lymphoma, Non-Hodgkin ; diagnosis ; drug therapy ; pathology ; surgery ; Lymphoma, T-Cell ; diagnosis ; drug therapy ; pathology ; surgery ; Male ; Middle Aged ; Neoplasm Staging ; Prednisone ; therapeutic use ; Retrospective Studies ; Salvage Therapy ; Survival Rate ; Vincristine ; therapeutic use ; Young Adult
5.Gastric Perforation Caused by Primary Gastric Diffuse Large B Cell Lymphoma.
Ju Seok KIM ; Woo Sun ROU ; Byung Moo AHN ; Hee Seok MOON ; Sun Hyung KANG ; Jae Kyu SUNG ; Hyun Yong JEONG ; Kyu Sang SONG
The Korean Journal of Gastroenterology 2015;65(1):43-47
Spontaneous gastric perforation is a rare complication of gastric lymphoma that is potentially life threatening since it can progress to sepsis and multi-organ failure. Morbidity also increases due to prolonged hospitalization and delay in initiating chemotherapy. Therefore prompt diagnosis and appropriate treatment is critical to improve prognosis. A 64-year-old man presented to the emergency department with severe abdominal pain. Chest X-ray showed free air below the right diaphragm. Abdominal CT scan also demonstrated free air in the peritoneal cavity with large wall defect in the lesser curvature of gastric lower body. Therefore, the patient underwent emergency operation and primary closure was done. Pathologic specimen obtained during surgery was compatible to diffuse large B cell lymphoma. Fifteen days after primary closure, the patient received subtotal gastrectomy and chemotherapy was initiated after recovery. Patient is currently being followed-up at outpatient department without any particular complications. Herein, we report a rare case of gastric lymphoma that initially presented as peritonitis because of spontaneous gastric perforation.
Abdominal Pain
;
Antigens, CD20/metabolism
;
Antigens, CD45/metabolism
;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
;
Gastrectomy
;
Humans
;
Intestinal Perforation/diagnostic imaging
;
Lymphoma, Large B-Cell, Diffuse/*diagnosis/drug therapy/pathology
;
Lymphoma, Non-Hodgkin/*diagnosis/drug therapy/pathology
;
Male
;
Middle Aged
;
Positron-Emission Tomography
;
Stomach Neoplasms/*diagnosis/drug therapy/pathology
;
Tomography, X-Ray Computed
6.Synchronous Hepatocellular Carcinoma and B-Cell Non-Hodgkin's Lymphoma in Chronic Hepatitis C Patient.
Soon Il LEE ; Nae Yun HEO ; Seung Ha PARK ; Young Don JOO ; Il Hwan KIM ; Jeong Ik PARK ; Ji Yeon KIM ; Seung Ho KIM ; Hye Kyung SHIM
The Korean Journal of Gastroenterology 2014;64(3):168-172
Hepatitis C virus (HCV) is one of the main viral causes of hepatocellular carcinoma (HCC) and is associated with lymphoproliferative disorder such as non-Hodgkin's lymphoma (NHL). However, there are only few case reports on concomitantly induced NHL and HCC by HCV. Herein, we report a case of synchronous NHL and HCC in a patient with chronic hepatitis C which was unexpectedly diagnosed during liver transplantation surgery. This case suggests that although intrahepatic lymph node enlargements are often considered as reactive or metastatic lymphadenopathy in chronic hepatitis C patients with HCC, NHL should also be considered as a differential diagnosis.
Antineoplastic Agents/therapeutic use
;
Carcinoma, Hepatocellular/complications/*diagnosis/radiotherapy
;
Drug Therapy, Combination
;
Embolization, Therapeutic
;
Fluorodeoxyglucose F18
;
Gadolinium DTPA
;
Genotype
;
Hepatitis B virus/genetics
;
Hepatitis C, Chronic/complications/*diagnosis/*virology
;
Humans
;
Liver Neoplasms/complications/*diagnosis/radiotherapy
;
Lymph Nodes/pathology
;
Lymphoma, Non-Hodgkin/complications/*diagnosis/drug therapy
;
Magnetic Resonance Imaging
;
Male
;
Middle Aged
;
Positron-Emission Tomography
;
Tomography, X-Ray Computed